☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
janssen
Janssen Reports the CHMP’s Positive Opinion of Balversa (Erdafitinib) to Treat Metastatic Urothelial Carcinoma (mUC)
June 28, 2024
Janssen Submits a Marketing Authorisation Application to the EMA for Lazertinib Plus Rybrevant to Treat Lung Cancer
December 23, 2023
PharmaShots Weekly Snapshots (October 09–13, 2023) _
October 14, 2023
Janssen Reports P-IIIb Study (ESCAPE-TRD) Results of Spravato (esketamine nasal spray) for Treatment-Resistant Major Depressive Di...
October 10, 2023
Janssen Reports P-III Study (MARIPOSA) Results of Rybrevant (amivantamab-vmjw) + Lazertinib for EGFR-Mutated Non-Small Cell Lung C...
September 29, 2023
Janssen Presents P-Ib/II Study (CHRYSALIS-2) Results of Rybrevant (amivantamab-vmjw) + Lazertinib for EGFR-Mutated Advanced NSCLC...
September 12, 2023
Load more...
Back to Home
Modal title
×
Modal body text goes here.